SCHEMBL2064518

SCHEMBL2064518

O=[As](O)(Oc1ccccc1)Oc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA4 P22748 2/20 0.46
CA9 Q16790 2/20 0.46
CA6 P23280 1/20 0.46
CA7 P43166 1/20 0.46
CA14 Q9ULX7 1/20 0.46
LTA4H P09960 2/20 0.41
TSHR P16473 1/20 0.41
SRC P12931 1/20 0.41
ALOX15 P16050 1/20 0.39
CA5A P35218 1/20 0.39
CA5B Q9Y2D0 1/20 0.39
TDP1 Q9NUW8 3/20 0.38
NR1H2 P55055 1/20 0.37
BAX Q07812 1/20 0.37
MAPT P10636 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
ALDH1A1 P00352 1/20 0.36
RECQL P46063 1/20 0.36
CA1 P00915 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28278624 0.88 CA4 (0.41) CA4CA9CA6CA7CA14
SCHEMBL27707183 0.86 CA9 (0.39) CA4CA9CA6CA7CA14
SCHEMBL367452 0.84 CA4 (0.46) CA4CA9CA6CA7CA14
SCHEMBL28220156 0.81 ALDH1A1 (0.50) CYP2C19ALDH1A1CA1CA2L3MBTL1
SCHEMBL26101859 0.80 GSR (0.39) CA4CA9CA6CA7CA14
SCHEMBL15477270 0.78 CA4 (0.52) CA4CA9CA6CA7CA14
SCHEMBL2001538 0.78 CA4 (0.41) CA4CA9CA6CA7CA14
SCHEMBL712975 0.78 LTA4H (0.45) CA4CA9CA6CA7CA14
SCHEMBL27576862 0.72 CA4 (0.35) CA4CA9CA6CA7CA14
SCHEMBL808465 0.72 CA4 (0.38) CA4CA9CA6CA7CA14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4724110-A1 PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY WUXI XDC SINGAPORE PRIVATE LIMITED (SG) 2026-04-15 EP claimed
US-20250188407-A1 PHYLLOBACTERIUM MYRSINACEARUM STRAIN N1N2-2 FOR EFFICIENT DEGRADATION OF DIPHENYLARSINIC ACID AND USE THEREOF China Construction Eighth Bureau Environmental Protection Technology Co., Ltd. (CN) 2025-06-12 US claimed
US-12325853-B1 Phyllobacterium myrsinacearum strain N1N2-2 for efficient degradation of diphenylarsinic acid and use thereof INSTITUTE OF SOIL SCIENCE, CAS (CN) 2025-06-10 US claimed
WO-2024251196-A1 PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY WUXI XDC (SHANGHAI) CO., LTD. (CN) 2024-12-12 WO claimed
CN-111465699-B Method for producing amines from carbonyl compounds by transaminase reaction under salt precipitation 恩齐米克斯公司 2024-09-20 CN claimed
CN-117625493-B Brevibacterium purpureum N1N2-2 capable of efficiently degrading diphenyl arsenate and application thereof 中国科学院南京土壤研究所 2024-07-26 CN claimed
US-12018303-B2 Method for preparing amines from carbonyl compounds by transaminase reaction under salt precipitation ENZYMICALS AG (DE) 2024-06-25 US claimed
CN-117625493-A Brevibacterium purpureum N1N2-2 capable of efficiently degrading diphenyl arsenate and application thereof 中国科学院南京土壤研究所 2024-03-01 CN claimed
US-20230116567-A1 METHOD FOR ANALYZING NUCLEIC ACID DRUGS MEDIFORD CORPORATION (JP) 2023-04-13 US claimed
CN-115151815-A Method for analyzing nucleic acid drug and the like 美迪恩斯生命科技株式会社 2022-10-04 CN claimed
CN-109897797-B Culture method of sulfate reducing strain, sulfate reducing strain and application 中国科学院烟台海岸带研究所 2022-03-18 CN claimed
EP-0070155-B1 PROCESS OF PREPARING A KETAZINE FROM A KETONE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1984-10-10 EP claimed
US-4473708-A REACTING KETONE WITH AMMONIA AND HYDROGEN PEROXIDE MITSUBISHI GAS CHEMICAL COMPANY INC. (JP) 1984-09-25 US claimed
EP-0070155-A1 Process of preparing a ketazine from a ketone MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1983-01-19 EP claimed
JP-7109284-A None JP disclosed
CN-122071421-A Process for efficiently preparing acrylamide monomer by low-cost base catalytic pyrolysis 深圳有为技术控股集团有限公司 2026-05-22 CN disclosed
EP-4724110-A1 PROCESS FOR PREPARING ANTIBODY-DRUG CONJUGATES WITH IMPROVED HOMOGENEITY WUXI XDC SINGAPORE PRIVATE LIMITED (SG) 2026-04-15 EP disclosed
EP-0070155-B1 PROCESS OF PREPARING A KETAZINE FROM A KETONE MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1984-10-10 EP disclosed
US-4473708-A REACTING KETONE WITH AMMONIA AND HYDROGEN PEROXIDE MITSUBISHI GAS CHEMICAL COMPANY INC. (JP) 1984-09-25 US disclosed
EP-0070155-A1 Process of preparing a ketazine from a ketone MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) 1983-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12018303-B2 Method for preparing amines from carbonyl compounds by transaminase reaction under salt precipitation GOT1, GOT2, OAT CA4 302/4885CA9 81/4885CA6 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.